Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Computacenter delivers 'good performance' in Q1

(Sharecast News) - Information technology services business Computacenter said on Thursday that it had delivered a "good performance" in Q1, which was ahead of the prior year and in line with internal expectations. Computacenter said group technology sourcing revenue increased "strongly" against a relatively soft comparison, largely driven by North America, while group services revenue was also ahead of FY24, reflecting "good growth" in professional services and a "slight decline" in managed services revenue.

By region, Computacenter said North America continued its momentum and delivered "a strong performance", reflecting the increased product order backlog position at the end of 2024, while the UK achieved "good growth" in technology sourcing and "excellent growth" in professional services. It also said it had "performed solidly" in Germany.

The FTSE 250-listed group stated that at the end of the quarter, its committed product order backlog across all regions "remained healthy", comfortably exceeding the prior year equivalent position.

However, with global political and macroeconomic uncertainty increasing in recent weeks, Computacenter said the potential impacts on customer demand were "difficult to predict", even though it highlighted it does not have any direct exposure to tariffs, as it meets all local demand with local supply within its markets.

"While we are mindful of the more uncertain backdrop, after an encouraging start to the year, we continue to believe we are well positioned to make progress for the year as a whole in constant currency and to gain market share," said Computacenter.

As of 0825 BST, Computcenter shares were up 2.32% at 2,466.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.